A randomized multicenter clinical trial of 99Tc-methylene diphosphonate in treatment of rheumatoid arthritis

作者:Mu, Rong; Liang, Jun; Sun, Lingyun; Zhang, Zhuoli; Liu, Xiangyuan; Huang, Cibo; Zhu, Ping; Zuo, Xiaoxia; Gu, Jieruo; Li, Xiangpei; Li, Xingfu; Liu, Yi; Feng, Ping; Li, Zhanguo*
来源:International Journal of Rheumatic Diseases, 2018, 21(1): 161-168.
DOI:10.1111/1756-185X.12934

摘要

AimTo investigate the efficacy and safety of technetium-99 conjugated with methylene diphosphonate (Tc-99-MDP, Yunke Pharmaceutical industry) in the treatment of rheumatoid arthritis (RA). @@@ MethodsA total of 120 patients with active RA were randomly divided into three groups: Group A (receiving oral meloxicam tablets); Group B (receiving intravenous drip of (TC)-T-99-MDP); Group C (receiving combination treatment of intravenous drip of Tc-99-MDP and oral meloxicam tablets). The main clinical and laboratory parameters were evaluated at baseline and after 14 days of therapy. @@@ ResultsAfter 14 days of treatment, American College of Rheumatology 20 response was 15.62%, 34.04% and 48.78% in the three groups, respectively. The incidence of adverse events in three groups were 3.13%, 8.51% and 9.76% respectly, and has no significant difference. In addition, biochemical markers of bone metabolism including bone alkaline phosphatase (BAP), tartrate resistant acid phosphatase (TRAP) and dickkopf-1 (DKK-1), all improved in the three groups, although more significant in Group B than Group A, and more significant in the combination group than monotherapy groups. @@@ Conclusion(99)Tc-MDP has good efficacy and safety in the treatment of active RA patients; the benefit was more remarkable when Tc-99-MDP was combined with NSAIDs. Tc-99-MDP may also have potential to improve bone metabolism.

全文